Safety of Meropenem and Vancomycin at 33 Weeks Gestation
Both meropenem and vancomycin can be safely used at 33 weeks gestation when clinically indicated for serious bacterial infections, with no evidence of fetal harm in human studies.
Meropenem Safety Profile
Meropenem has insufficient human data to establish drug-associated risk for major birth defects or miscarriages, but the available evidence is reassuring 1. Animal studies in pregnant rats and monkeys at doses up to 2.4 and 2.3 times the maximum recommended human dose showed no fetal toxicity or malformations during organogenesis 1.
A recent 2026 retrospective cohort study of pregnant women with upper urinary tract infections found that meropenem was primarily used in the third trimester (which includes 33 weeks) for severe infections including sepsis and septic shock 2. The study demonstrated:
- No maternal deaths in the meropenem group
- Similar rates of adverse pregnancy outcomes compared to ceftriaxone-treated controls
- Lower Apgar scores in the meropenem group, but this was attributed to the severity of maternal illness rather than drug toxicity 2
The FDA classifies meropenem with no established pregnancy category but notes it is excreted in breast milk 1. Clinical experience from Japanese obstetric infections showed a 97.4% response rate with no adverse reactions in pregnant patients 3.
Vancomycin Safety Profile
Vancomycin has more robust human pregnancy data. The FDA label states that vancomycin was studied in a controlled clinical trial where it was administered to pregnant women for serious staphylococcal infections in the second and third trimesters 4. Key findings:
- Vancomycin was detected in cord blood
- No sensorineural hearing loss or nephrotoxicity attributable to vancomycin was noted in infants 4
- One infant had conductive hearing loss that was not attributed to vancomycin and resolved spontaneously 4
A dedicated 1989 study of 10 pregnant women receiving IV vancomycin for methicillin-resistant Staphylococcus aureus infections confirmed that vancomycin use during the second and third trimesters does not produce sensorineural hearing loss or nephrotoxicity in the infant 5. Auditory brainstem response testing and renal function studies were normal in all infants 5.
Clinical Recommendations
Use both antibiotics when indicated for serious infections at 33 weeks gestation, as the benefits clearly outweigh theoretical risks:
Meropenem: Reserve for severe infections, sepsis, or multidrug-resistant organisms. The 2022 guideline on multidrug-resistant organisms provides specific neonatal dosing, indicating acceptance of use near term 6
Vancomycin: Safe for methicillin-resistant gram-positive infections throughout pregnancy, with established human safety data 4, 5
Monitor appropriately: Ensure therapeutic drug levels are achieved, as pregnancy physiology may alter pharmacokinetics 7
Important Caveats
The combination of vancomycin and meropenem may have antagonistic effects in certain bacterial biofilm scenarios, though this is based on in vitro data for prosthetic joint infections 8. This should not deter use in life-threatening maternal infections where broad coverage is needed.
Both drugs are excreted in breast milk, but this is not a contraindication to use 1, 4
At 33 weeks gestation, you are in the third trimester where most safety data exists for both antibiotics, making this an optimal time for use if needed compared to first trimester exposure